

# Is serum retinol binding protein-4: A predictor for diabetes in genetically high risk population?

K. Subhash Chandra Bose, Shachin K. Gupta<sup>1</sup>, Sandeep Singh<sup>2</sup>

Departments of Biochemistry, <sup>1</sup>Medicine, <sup>2</sup>Forensic Medicine and Toxicology, L. N. Medical College and Research Centre, Kolar Road, Bhopal, Madhya Pradesh, India

**Background:** Retinol binding protein-4 (BP-4) a new adipocytokine, specifically binds to retinol, through experimental studies, reported its link between obesity and insulin resistance (IR). But till date no studies are available on influence of genetic predisposition of diabetes on RBP-4 expression. Hence, we aimed to study the influence of genetic predisposition of diabetes on the serum RBP-4 and its role in development of IR and diabetes in genetically high risk population. **Materials and Methods:** Healthy non diabetic individuals (age 18 to 22) were grouped into Group I: Control ( $n = 81$ ), whose parents are non diabetic, non hypertensive and does not have any family history of coronary heart diseases. Group II: ( $n = 157$ ) with one of their parents diabetic and Group III: ( $n = 47$ ) with both parents diabetic. In all the participants, we estimated fasting serum RBP-4, insulin and glucose. Homeostasis model for assessment-insulin resistance (HOMA-IR) and homeostasis model for assessment-beta cell dysfunction (HOMA-B) were calculated from fasting serum insulin and glucose levels. **Results:** In this study, we observed significantly higher RBP-4 levels  $12.71 \pm 2.3$  in Group-II and  $13.25 \pm 2$  in Group-III, respectively when compared to Group-I  $11.4 \pm 1.8$  ( $P < 0.01$ ). RBP-4 showed a significantly strong positive correlation with plasma insulin, glucose and HOMA-IR in genetically high risk population (group II and III)  $P < 0.01$ . Linear regression analysis revealed a strong positive association of RBP-4 with parental diabetes even after adjusting for BMI, age and sex (OR 1.53, 95% CI 1.089-1.40). **Conclusion:** Higher serum RBP-4 and its positive correlation with Insulin, glucose, and HOMA-IR in healthy non diabetic participants of genetically high risk population, indicating its role as predictor for the onset of diabetes in coming future.

**Key words:** Adipocytokines, diabetes, insulin resistance, retinol binding protein-4

## INTRODUCTION

In recent times, the status of adipose tissue has changed from mere source of energy store to endocrine organ on discovery of many adipokines and their role in energy homeostasis.<sup>[1]</sup> RBP-4 a new adipose tissue derived cytokine which specifically binds to retinol, has recently been reported to prove a link between obesity and insulin resistance. It was first found to be expressed in rodent adipocytes in 1992 by Tsutsumi C *et al.*<sup>[2]</sup> Later RBP-4 was identified as an adipocytokine that is increased in circulation in mouse models of obesity and insulin resistance.<sup>[3]</sup> In the experimental study done by Yong Q *et al.*<sup>[4]</sup> they observed over expression of RBP-4 in adipose tissue of adipocyte specific GLUT4 knockout mouse.

Furthermore, they observed development of insulin resistance in mice that were either over expressing RBP-4 or were injected with recombinant RBP-4, where as RBP-4 knockout mice showed increased insulin sensitivity. Treatment of GLUT4 knockout mice with TZD resulted in decreased RBP-4 expression, though there was no change in RBP-4 expression in control mice. In addition to animal studies, few human studies done by<sup>[5-7]</sup> showed positive correlation of RBP-4 with insulin resistance and diabetes. Very few studies like study done by Qibin Qi *et al.*<sup>[8]</sup> are available on RBP-4 levels in different ethnic population, but no studies are available on the influence of genetic predisposition of diabetes on RBP-4 expression. As per international diabetic federation India is so called as diabetic capital of the world, with already existing 50.8 million diabetic patients and expected to raise up to 87 million by 2030,<sup>[9]</sup> not even single study is done till date from Indian subcontinent on the influence of RBP-4 in diabetes. Hence in this study, we investigated the RBP-4 expression and its role in development of insulin resistance and diabetes in genetically high risk population, so that a new pharmacological, diagnostic and prognostic approach can be made in treating diabetes.

| Access this article online |  |
|----------------------------|--|
| Quick Response Code:       | Website:<br><a href="http://www.journals.mui.ac.ir/jrms">www.journals.mui.ac.ir/jrms</a> |
|                            | DOI:<br>***  |

**Address for correspondence:** Dr. K. Subhash Chandra Bose, Department of Biochemistry, L. N. Medical College and Research Centre, Kolar Road, Bhopal, Madhya Pradesh, India. E-mail: kscbreddy@gmail.com

**Received:** 28-06-2012; **Revised:** 21-07-2012; **Accepted:** 28-08-2012

## MATERIALS AND METHODS

This cross sectional study was done in 2011 at L. N. Medical college-Bhopal, INDIA and is approved by institutional ethics committee with wide Ref No: IEC/3/2011 and written consent was taken from all participants. For this study we selected three groups.

Group I: Control group consists ( $n = 81$ ) both male and female of age group between 18 to 22 years, irrespective of BMI whose parents are non diabetic, non hypertensive and does not have any family history of coronary heart diseases.

Group II: ( $n = 157$ ) both male and female of age group between 18 to 22 years, irrespective of BMI with one of their parents with history of type 2 diabetes.

Group III: ( $n = 47$ ) both male and female of age group between 18 to 22 years, irrespective of BMI, with both parents having history of type 2 diabetes.

### Exclusion criteria

None of the subjects from above groups are diabetic, pregnant, gestational diabetic and none of their parents were type 1 diabetic. The diabetes in these subjects was excluded by through applying WHO criteria.<sup>[10]</sup>

### Measurements

All the subjects of above groups are on overnight fasting. In all the above subjects we measured serum glucose by commercial kits for Biosystems A25 fully auto analyzer. Serum insulin and RBP-4 were estimated by ELISA method with commercial kits.

Insulin resistance and  $\beta$  cell dysfunction were measured by homeostasis model for assessment (HOMA) based on formula:<sup>[11]</sup>

$HOMA-IR = \text{fasting serum insulin } (\mu\text{IU/ml}) \times \text{fasting serum glucose (mg/dl)} / 405$

$HOMA-B = \text{fasting serum insulin } (\mu\text{IU/ml}) \times 3.33 / (\text{fasting serum glucose (mg/dl)} - 3.5)$ .

### Statistical analysis

ANOVA is applied to see the statistical difference in the mean values of serum biological parameters, BMI, HOMA-IR and HOMA-B between three groups. Simple student *t*-test was applied to see the difference in the mean values of RBP-4 and other diabetic markers between two groups. Relationship between continuous variables was expressed by applying Pearson's correlation (*r*) for normally distributed variables and Spearman's correlation for non parametric distribution. Descriptive results of continuous

variables are expressed as mean  $\pm$  SD for normally distributed or as median for nonparametrically distributed variables. *P* value  $<0.05$  is considered significant and  $<0.01$  as highly significant. Multivariate logistic regression was performed in stepwise manner to evaluate the association among independent and dependent variables. All the data were analyzed using statistical software SPSS version-16 Chicago USA.

## RESULTS

### Serum RBP-4 and other biological parameters in different study groups

As shown in Table 1, serum RBP-4 levels are significantly high in genetically high risk population with  $13.25 \pm 2$  in both parents diabetic group and  $12.71 \pm$  in single parent diabetic group when compared to control group whose RBP-4 levels are  $11.44 \pm 1.8$  ( $P < 0.001$ ). The same variation in other known diabetic markers like fasting glucose, insulin, HOAM-IR and BMI were observed between study groups and control ( $P < 0.01$ ).

### Serum RBP-4 and other biological parameters between single and both parents diabetic population

Table 2 shows statistically high significant difference in serum RBP-4, Insulin, glucose and HOMA-IR between these two groups with highest levels in children of both diabetic parents group ( $P < 0.01$ ). But at the same time no statistical difference in mean BMI and HOMA-B levels between these two groups ( $P > 0.05$ ).

### Gender difference in serum biological parameters

In this study, we observed no mean difference in serum biological parameters like insulin in males  $10.17 \pm 2$  and in females  $10.36 \pm 1.6$  ( $P > 0.05$ ), glucose in males  $77.44 \pm 44$  and  $77.39 \pm 10.2$  in females ( $P > 0.05$ ), RBP-4 in males  $12.28 \pm 3.3$  and  $11.98 \pm 2.7$  in females ( $P > 0.05$ ), BMI in males  $22.67 \pm 3.7$  and  $22.29 \pm 3.9$  in females ( $P > 0.05$ ). The same no variation in HOMA-IR and B between male and female participants ( $P > 0.05$ ) was observed.

### Correlation and association of different diabetic markers with RBP-4 in genetically high risk population

In examining the relationship between serum RBP-4 and other biological markers for diabetes in genetically high risk population before the onset of diabetes, we observed highest significant positive correlation of BMI with RBP-4 (Pearson coefficient 0.844) followed by HOMA-IR (Pearson coefficient 0.47) and fasting glucose (Pearson coefficient 0.439). No statistically significant correlation was observed between RBP-4 and HOMA-B with Pearson coefficient 0.002 ( $P > 0.5$ ).

In assessing the association of RBP-4 and other diabetic markers in study population, Table 3 showing the logistic




Figure 1: Relationship between RBP-4 and diabetogenic factors

Table 1: One-way ANOVA (analysis of variance) of biological parameters between three study groups

| Parameters                    | Non diabetic (n=81) | Single parent diabetic (n=157) | Both parents diabetic (n=47) | P value  |
|-------------------------------|---------------------|--------------------------------|------------------------------|----------|
| BMI (kg/m <sup>2</sup> )      | 21.8±3.3            | 22.4±4.1                       | 23.6±3.5                     | 0.042*   |
| Fasting serum insulin (µU/ml) | 8.06±0.99           | 10.79±1.5                      | 11.12±1.3                    | <0.001** |
| Fasting serum glucose (mg/dl) | 73.4±8.5            | 78.02±10.1                     | 82.4±9.7                     | <0.001** |
| Fasting serum RBP-4 (µg/ml)   | 11.44±1.8           | 12.71±2.3                      | 13.25±2.0                    | <0.001** |
| HOMA-IR                       | 1.45±0.23           | 2.09±0.49                      | 2.26±0.41                    | <0.001** |
| HOMA-B                        | 0.39±0.07           | 0.48±0.07                      | 0.47±0.07                    | <0.001** |

BMI=Body Mass Index, RBP-4=Retinol binding protein-4, HOMA-IR=Homeostasis model assessment-insulin resistance, HOMA-B=Homeostasis model assessment-beta cell function. Results are presented as mean±SD. \*\*P<0.01; \*P<0.05

Table 2: Mean difference in serum RBP-4 and other biomarkers between single parent diabetic and both parents' diabetic groups

| Parameters            | Single parent diabetic group (n=147) | Both parents diabetic group (n=47) | P value |
|-----------------------|--------------------------------------|------------------------------------|---------|
| BMI                   | 22.48±4.1                            | 23.63±3.5                          | 0.086#  |
| Fasting serum insulin | 10.79±1.5                            | 11.12±1.3                          | 0.192#  |
| Fasting serum glucose | 78.0±10.9                            | 82.44±9.7                          | 0.010** |
| HOMA-IR               | 2.09±0.49                            | 2.26±0.41                          | 0.030*  |
| HOMA-B                | 0.48±0.07                            | 0.47±0.07                          | 0.339#  |
| Fasting serum RBP-4   | 12.17±2.3                            | 13.25±0.07                         | 0.006** |

BMI=Body Mass Index, RBP-4=Retinol binding protein-4, HOMA-IR=Homeostasis model assessment-insulin resistance, HOMA-B=Homeostasis model assessment-beta cell function. Results are presented as mean±SD. \*\*P<0.01; \*P<0.05; #P>0.5

regression in stepwise manner with parental diabetes as dependent variable, we observed a significant positive association of RBP-4 with the risk of developing diabetes in genetically high risk population with OR 1.235 and P 001.

Table 3: Multivariate logistic regression in stepwise manner to assess the association of RBP-4 with parental diabetes

| Parameter        | Odds ratio (or) | 95% confidence interval CI | P value |
|------------------|-----------------|----------------------------|---------|
| BRP-4            | 1.23            | 1.08-1.40                  | 0.001** |
| Unadjusted       | 1.49            | 1.18-1.87                  | 0.001** |
| Adjusted for BMI | 1.24            | 1.09-1.41                  | 0.001** |
| Adjusted for age | 1.26            | 1.11-1.44                  | 0.000** |
| Adjusted for sex |                 |                            |         |

BMI=Body Mass Index, RBP-4=Retinol binding protein-4. \*\*P<0.01

## DISCUSSION

In the present study, we observed that serum RBP-4 levels were elevated in study groups of genetically high risk population (P<0.01) when compared to study group from low risk population indicating its potential role in initiating and propagating diabetes, metabolic syndrome and coronary heart

diseases in genetically predisposed population. Young Min Cho *et al.*<sup>[6]</sup> in their study on RBP-4 levels in type 2 diabetes and impaired glucose tolerance also observed very higher serum RBP-4 ( $18.9 \pm 11.2$ ). As expecting there is a gross variation in serum fasting glucose, insulin and levels of HOMA-IR in genetically predisposed healthy individuals when compared to their counterparts whose parents are non diabetic.

At the same time this study showed statistically significant difference in serum RBP-4 with highest levels in individuals whose both parents are diabetic than that of individuals of single parent diabetic ( $P < 0.01$ ), suggesting the genetic variation in the expression of RBP-4. There might be some metabolites expressing either abnormally or over expressed in genetically predisposed population, who might influencing the levels of RBP-4 and its adverse role in developing diabetes.

In this study from Figure 1a, we observed positive correlation between BMI and RBP-4 with Pearson coefficient 0.844 in genetically high risk population for diabetes indicating its direct role in initiating metabolic syndrome. In a significant study done by Gragam T E *et al.*,<sup>[5]</sup> they also observed same positive association with BMI. In a recent study done by Lee DC *et al.*<sup>[12]</sup> on the association of RBP-4 and insulin resistance in healthy adolescents also observed linear positive correlation between RBP-4 and BMI.

As shown in Figure 1b from our study, we observed that as serum RBP-4 increases serum insulin is also increases predicting its crucial role in creating hyperinsulinemia like environment which prevails in type 2 diabetes. Our hypothesis strongly supported by Kotani K *et al.*<sup>[13]</sup> study. In their study on treating adip-GLUT-4<sup>-/-</sup> mice with rosiglitazone, an activator of peroxisome proliferator-activated receptor gamma (PPAR) reversed increased adipocyte RBP-4 mRNA expression and reversing insulin resistance.

From Figure 1c in this study, we observed close correlation between RBP-4 and HOMA-IR depicting its role in developing insulin resistance (IR). It may be through retinol dependent and or retinol independent mechanisms. Retinoids can stimulate phosphoenolpyruvate carboxykinase (PEPCK) expression in liver and hepatic gluconeogenesis.<sup>[14]</sup> In addition, retinol is a precursor for the synthesis of ligands of retinoic acid receptor and retinoid X receptor. These are the partners of the peroxisome-proliferator-activated receptor family that regulates gene control to fatty acid metabolism.<sup>[15,16]</sup> RBP-4 could thus be linked to insulin resistance through impaired fatty acid metabolism. Yong Q (3) *et al.* in their experimental study observed increased expression of several retinoid-responsive genes, retinoic acid receptor-2, stearoyl CoA desaturase-1 and acetyl CoA carboxylase in muscle of

RBP-4 transgenic mice, thus increased delivery of retinol by RBP-4 might explain its effect on IR.

The same positive correlation between RBP-4 and glucose was observed in study population whose parents are diabetic [Figure 1d], indicating its glucogenic effect. Yong Q<sup>[2]</sup> *et al.* also showed that RBP-4 directly stimulates PEPCK expression and glucose production in cell culture, suggesting its direct effect on hyperglycemia. But from Figure 1e we observed no correlation between RBP-4 and HOMA-B indicating no probable role regulation, expression and release of insulin from beta cells.

In contrast to few studies,<sup>[17,18]</sup> we observed no gender difference in serum RBP-4 levels between male and females. This may be due to the age group which we selected.

## CONCLUSION

From this study though we observed no gender difference in RBP-4 expression, statistically significant higher serum RBP-4 and its positive correlation with insulin, glucose, BMI and HOMA-IR in health non diabetic participants of genetically high risk population was observed, signifying its role in initiation and propagation of progressive degenerative diseases like diabetes. At the same time before any significant changes in diabetic markers we observed elevated serum RBP-4 in genetically high risk population indicating its role as predictor for the onset of diabetes in coming future.

## ACKNOWLEDGMENTS

The authors are very much thankful to The Director, M.P. Council of Science and Technology (MPCOST) Gov. of Madhya Pradesh, for their financial support to this study with wide sanction letter No. 6089/CST/BTAC/2011.

## REFERENCES

1. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab* 2004;89:2448-556.
2. Tsutsumi C, Okuno M, Tannous L, Piantedosi R, Allan M, Goodman DS, *et al.* Retinoids and retinoid-binding protein expression in rat adipocytes. *J Biol Chem* 1992;267:1805-10.
3. Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F, Kahn BB. Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. *J Biol Chem* 1993;268:2243-6.
4. Yong Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, *et al.* Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. *Nature* 2005;436:356-62.
5. Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, *et al.* Retinol binding protein 4 and insulin resistance in lean, obese and diabetic subjects. *N Engl J Med* 2006;354:2552-63.
6. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, *et al.* Retinol binding protein 4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. *Diabetes Care* 2006;29:2457-61.

7. Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, *et al.* Retinol binding protein 4 in human obesity. *Diabetes* 2006;55:2805-10.
8. Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, *et al.* Elevated retinol binding protein 4 levels are associated with metabolic syndrome in Chinese people. *J Clin Endocrinol Metab* 2007;92:4827-34.
9. IDF Diabetes Atlas, 4<sup>th</sup> ed. Belgium: International Diabetic Federation; 2009. p. 27. Available from: [http://www.idf.org/sites/default/files/The\\_Global\\_Burden.pdf](http://www.idf.org/sites/default/files/The_Global_Burden.pdf) [Last accessed on 26 May 2012].
10. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications report of a WHO consultation. Part I: Diagnosis and classification of diabetes mellitus (WHO/NCD/CS/99.2). Geneva: World Health Organization; 1999.
11. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment. Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985;28:412-9.
12. Lee DC, Lee JW, Lm JA. Association of serum retinol binding 4 and insulin resistance in apparently healthy adolescents. *Metabolism* 2007;36:327-31.
13. Kotani K, Kim YB, Peroni O, Mundt A, Kahn BB. Rosiglitazone treatment normalizes glucose tolerance in adipose-specific GLUT4 knockout mice but renders muscle-specific GLUT4 more diabetic (Abstract). Philadelphia, PA: Paper presented at 61<sup>st</sup> scientific sessions of American Diabetes Association; 2001 June 22-26.
14. Aeberli I, Biebinger R, Lehmann R, L'allemand D, Spinass GA, Zimmermann MB. Serum retinol binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. *J Clin Endocrinol Metab* 2007;92:4359-65.
15. Wolf G. Serum retinol binding protein: A link between obesity, insulin resistance, and type 2 diabetes. *Nutr Rev* 2007;65:251-6.
16. Ferre P. The biology of peroxisome proliferator-activated receptors-relationship with lipid metabolism and insulin sensitivity. *Diabetes* 2004;53:S43-50.
17. Mallat Z, Simon T, Benessiano J, Clement K, Taleb S, Wareham NJ, *et al.* Retinol binding protein 4 and prediction of incident coronary events in healthy men and women. *J Clin Endocrinol Metab* 2009;94:255-60.
18. Nehal H EL-Said, Randa F Abd E Salam, Nagwa Abd EL-Ghaffar Mohammad. Retinol binding protein 4 and insulin resistance in Egyptian type 2 diabetes. *Aust J Basic Appl Sci* [internet] 2011;5:265-71. Available from: <http://www.ajbasweb.com/ajbas/2011/October-2011 / 265-271.pdf> [Last accessed on 26 May 2012].

**How to cite this article:** Bose KSC, Gupta SK, Singh S. Is serum retinol binding protein-4: A predictor for diabetes in genetically high risk population?. *J Res Med Sci* 2012;17:1015-9.

**Source of Support:** The Director, M.P. Council of Science and Technology (MPCOST) Gov. of Madhya Pradesh, for their financial support to this study with wide sanction letter No. 6089/CST/BTAC/2011, **Conflict of Interest:** None declared.